Related references
Note: Only part of the references are listed.Cannabinoid receptor stimulation increases motivation for nicotine and nicotine seeking
Islam Gamaleddin et al.
ADDICTION BIOLOGY (2012)
Blockade of Nicotine Reward and Reinstatement by Activation of Alpha-Type Peroxisome Proliferator-Activated Receptors
Paola Mascia et al.
BIOLOGICAL PSYCHIATRY (2011)
Granular Insular Cortex Inactivation as a Novel Therapeutic Strategy for Nicotine Addiction
Benoit Forget et al.
BIOLOGICAL PSYCHIATRY (2010)
The selective dopamine D3 receptor antagonist SB 277011-A, but not the partial agonist BP 897, blocks cue-induced reinstatement of nicotine-seeking
Maram A. T. M. Khaled et al.
INTERNATIONAL JOURNAL OF NEUROPSYCHOPHARMACOLOGY (2010)
Noradrenergic α1 Receptors as a Novel Target for the Treatment of Nicotine Addiction (vol 35, pg 1751, 2010)
Benoit Forget et al.
NEUROPSYCHOPHARMACOLOGY (2010)
Central side-effects of therapies based on CB1 cannabinoid receptor agonists and antagonists: focus on anxiety and depression
Fabricio A. Moreira et al.
BEST PRACTICE & RESEARCH CLINICAL ENDOCRINOLOGY & METABOLISM (2009)
Rimonabant: an antagonist drug of the endocannabinoid system for the treatment of obesity
Carlos E. Leite et al.
PHARMACOLOGICAL REPORTS (2009)
Inhibition of fatty acid amide hydrolase reduces reinstatement of nicotine seeking but not break point for nicotine self-administration-comparison with CB1 receptor blockade
Benoit Forget et al.
PSYCHOPHARMACOLOGY (2009)
The future of endocannabinoid-oriented clinical research after CB1 antagonists
Bernard Le Foll et al.
PSYCHOPHARMACOLOGY (2009)
Blocking cannabinoid CB1 receptors for the treatment of nicotine dependence:: insights from pre-clinical and clinical studies
Bernard Le Foll et al.
ADDICTION BIOLOGY (2008)
Inhibition of Anandamide Hydrolysis by Cyclohexyl Carbamic Acid 3′-Carbamoyl-3-yl Ester (URB597) Reverses Abuse-Related Behavioral and Neurochemical Effects of Nicotine in Rats
Maria Scherma et al.
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS (2008)
Anandamide inhibits metabolism and physiological actions of 2-arachidonoylglycerol in the striatum
Mauro Maccarrone et al.
NATURE NEUROSCIENCE (2008)
The anandamide transport inhibitor AM404 reduces ethanol self-administration
Andrea Cippitelli et al.
EUROPEAN JOURNAL OF NEUROSCIENCE (2007)
Anxiolytic-like properties of the anandamide transport inhibitor AM404
Marco Bortolato et al.
NEUROPSYCHOPHARMACOLOGY (2006)
Pharmacological characterization of hydrolysis-resistant analogs of oleoylethanolamide with potent anorexiant properties
Giuseppe Astarita et al.
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS (2006)
Modulation of neuropathic and inflammatory pain by the endocannabinoid transport inhibitor AM404 [N-(4-hydroxyphenyl)-eicosa-5,8,11,14-tetraenamide]
G. La Rana et al.
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS (2006)
Endocannabinoids and β-amyloid-induced neurotoxicity in vivo:: effect of pharmacological elevation of endocannabinoid levels
M. van der Stelt et al.
CELLULAR AND MOLECULAR LIFE SCIENCES (2006)
Cannabinoid CB1 receptors control conditioned drug seeking
TJ De Vries et al.
TRENDS IN PHARMACOLOGICAL SCIENCES (2005)
Characterization of the fatty acid amide hydrolase inhibitor cyclohexyl carbamic acid 3′-carbamoyl-biphenyl-3-yl ester (URB597):: Effects on anandamide and oleoylethanolamide deactivation
D Fegley et al.
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS (2005)
Cannabinoid CB1 receptor antagonists as promising new medications for drug dependence
B Le Foll et al.
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS (2005)
Experimental Parkinsonism alters anandamide precursor synthesis, and functional deficits are improved by AM404: A modulator of endocannabinoid function
E Fernandez-Espejo et al.
NEUROPSYCHOPHARMACOLOGY (2004)
Selective inhibition of anandamide cellular uptake versus enzymatic hydrolysis -: a difficult issue to handle
CJ Fowler et al.
EUROPEAN JOURNAL OF PHARMACOLOGY (2004)
The molecular logic of endocannabinoid signalling
D Piomelli
NATURE REVIEWS NEUROSCIENCE (2003)
Cannabinoid receptors and their endogenous ligands
T Sugiura et al.
JOURNAL OF BIOCHEMISTRY (2002)
An endogenous capsaicin-like substance with high potency at recombinant and native vanilloid VR1 receptors
SM Huang et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2002)
Characterization of a novel endocannabinoid, virodhamine, with antagonist activity at the CB1 receptor
AC Porter et al.
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS (2002)
Biosynthesis and degradation of anandamide and 2-arachidonoylglycerol and their possible physiological significance
T Sugiura et al.
PROSTAGLANDINS LEUKOTRIENES AND ESSENTIAL FATTY ACIDS (2002)
2-Arachidonyl glyceryl ether, an endogenous agonist of the cannabinoid CB1 receptor
L Hanus et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2001)
Levels, metabolism, and pharmacological activity of anandamide in CB1 cannabinoid receptor knockout mice:: Evidence for non-CB1, non-CB2 receptor-mediated actions of anandamide in mouse brain
V Di Marzo et al.
JOURNAL OF NEUROCHEMISTRY (2000)
N-acyl-dopamines:: novel synthetic CB1 cannabinoid-receptor ligands and inhibitors of anandamide inactivation with cannabimimetic activity in vitro and in vivo
T Bisogno et al.
BIOCHEMICAL JOURNAL (2000)
Overlap between the ligand recognition properties of the anandamide transporter and the VR1 vanilloid receptor: inhibitors of anandamide uptake with negligible capsaicin-like activity
L De Petrocellis et al.
FEBS LETTERS (2000)
The endocannabinoid system as a target for therapeutic drugs
D Piomelli et al.
TRENDS IN PHARMACOLOGICAL SCIENCES (2000)
Share Paper
